Corporate ActionJul 22, 2026, 05:21 PM
Dyne Therapeutics Prices Upsized $375M Public Offering of Common Stock
AI Summary
Dyne Therapeutics priced an upsized underwritten public offering of 18.3 million shares of its common stock at $20.50 per share, expecting gross proceeds of $375.15 million. The company also granted underwriters an option to purchase up to an additional 2.745 million shares. Net proceeds are estimated to be $352.1 million, potentially reaching $405.0 million if the option is fully exercised. These funds, combined with existing capital and a recent $50 million loan tranche, are projected to extend the company's cash runway into the second quarter of 2028.
Key Highlights
- Priced upsized public offering of 18.3 million common shares.
- Public offering price set at $20.50 per share.
- Expected gross proceeds of $375.15 million from the offering.
- Underwriters have option for additional 2.745 million shares.
- Estimated net proceeds of $352.1 million, up to $405.0 million if option exercised.
- Proceeds, with existing cash, extend cash runway into Q2 2028.
- Closing of the offering expected around July 23, 2026.
Price Impact
More from DYN